Treatment of Malignant Midgut Carcinoid Tumours with A Long-Acting Somatostatin Analogue Octreotide

References

• Moertel C G, Sauer W G, Dockerty M B, Baggentoss AH. Life history of the carcinoid tumour of the small intestine. Cancer 1961; 14: 901–12
   PubMed Web of Science ®Google Scholar
• Graham-Smith DG. The carcinoid syndrome. William-Heineman Medical Books Ltd, London 1972
   Google Scholar
• Norheim I, Theodorsson-Norheim E, Brodin E, Öberg K. Tachykinins in carcinoid tumors. Their use as a tumor marker and possible role in carcinoid flush. J Clin Endocrinol Metab 1986; 63: 605–12
   PubMed Web of Science ®Google Scholar
• Brown H. Serotonin producing tumours. Serotonin in health and disease, Essman. Spectrum, New York 1977; 393–423
   Google Scholar
• Engelman K, Lovenberg W, Sjoerdsma A. Inhibition of serotonin synthesis by parachlorophenylalanine in patients with the carcinoid syndrome. N Engl J Med 1967; 277: 1103–8
   PubMed Web of Science ®Google Scholar
• Moertel CG. Treatment of the carcinoid tumour and the malignant carcinoid syndrome. J Clin Oncol 1983; 1: 727–40
   PubMed Web of Science ®Google Scholar
• Raptis S, Schlegel W, Pfeiffer EF. Effects of somatostatin on gut and pancreas. Gut hormones, S R Bloom. Churchill-Livingstone, Edinburgh 1978; 446–52
   Google Scholar
• Frölich J, Bloomgarden Z, Oates J. The carcinoid flush provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 1978; 299: 1055–7
   PubMed Web of Science ®Google Scholar
• del Pozo E, Neufeld M, Schlüter K, et al. Endocrine profile of a long-acting somatostatin derivative SMS 201–995; Study in normal volunteers following subcutaneous administration. Acta Endocrinol 1986; 111: 433–9
   PubMedGoogle Scholar
• Kraenzlin M E, Ch'ng JLC, Wood S M, Carr D H, Bloom SR. Long-term treatment of a VIP-oma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88: 185–7
   PubMed Web of Science ®Google Scholar
• Wood S M, Kraenzlin M E, Adrian T E, Bloom SR. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue; symptomatic and peptide responses. Gut 1985; 26: 438–44
   PubMed Web of Science ®Google Scholar
• Eriksson B, Öberg K, Andersson T, Lundqvist G, Wide L, Wilander E. Treatment of malignant endocrine pancreatic tumours with a new long-acting somatostatin analogue SMS 201–995. Scand J Gastroenterol 1988; 23: 508–12
   PubMed Web of Science ®Google Scholar
• Kvols L K, Moertel CG., O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663–6
   PubMed Web of Science ®Google Scholar
• Grimelius L. A silver nitrate stain for α2 cells in human pancreatic islets. Acta Soc Med Ups 1968; 73: 243–70
   PubMedGoogle Scholar
• Grimelius L, Wilander E. Silverstains in the study of endocrine cells of the gut and pancreas. Invest Cell Path 1980; 3: 3–12
   PubMedGoogle Scholar
• Wahlund K G, Edlen BJ. Simple and rapid determination of 5-hydroxyindole-3-acetic acid in urine by direct injection on a liquid chromatographic column. Clin Chim Acta 1981; 110: 71–6
   PubMed Web of Science ®Google Scholar
• Theodorsson-Norheim E, Norheim I, Öberg K, Brodin E, Lundberg J M, Tatemoto K. Neuropeptide K: a major tachykinin in plasma and tumor tissues from patients with carcinoid tumours. Biochem Biophys Res Commun 1985; 131: 77–83
   PubMed Web of Science ®Google Scholar
• Reubi J C, Mauser R, von Werder K, Torhorst J, Klijn J GN, Lamberts S WJ. Somatostatin receptors in human endocrine tumours. Cancer Res 1987; 47: 551–8
   PubMed Web of Science ®Google Scholar
• Reubi JC. A somatostatin analogue inhibits chrondrosarcoma and insulinoma tumour growth. Acta Endocrinol 1985; 109: 108–14
   PubMedGoogle Scholar
• Redding T W, Schally AV. Inhibition of growth of pancreatic carcinomas in animal models by analogues of hypothalamic hormones. Proc Natl Acad Sci USA 1984; 81: 248–52
   PubMed Web of Science ®Google Scholar
• Reichlin S. Somatostatin (second of two parts). N Engl J Med 1983; 25: 1556–63
   Google Scholar
• Öberg K, Norheim I, Lind E, et al. Treatment of malignant carcinoid tumours with human leukocyte interferon: Long-term results. Cancer Treat Rep 1986; 70: 1297–1304
   PubMedGoogle Scholar
• Hansen L E, Schrumpf E, Kolbenstvedt A N, Tausjo J, Dolva LO. Recombinant human alpha2-interferon in the treatment of metastatic midgut carcinoid tumours. J Interferon Res 1982; 7: 735, Abstract.
   Google Scholar
• Andersson T, Wilander E, Eriksson B, Lindgren P G, Öberg K. Effects of interferon on tumour tissue content in liver metastases of carcinoid tumours. Cancer Res 1990; 50: 3413–5
   PubMed Web of Science ®Google Scholar